Related Experiment Video
Updated: Jul 14, 2026
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID
Christiane Thallinger1, Johannes Werzowa, Wolfgang Poeppl
1Division of Clinical Pharmacokinetics, Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, Austria.
Abstract:
This study compares the antineoplastic potential of a novel treatment strategy combining cell cycle inhibitor-779 (CCI-779) plus dacarbazine (DTIC) versus DTIC monotreatment, the current chemotherapeutic mainstay in combating metastatic melanoma. A controlled four-group parallel study design comprising 24-40 mice per tumor cell line was used in a severe combined immunodeficiency (SCID)-mouse xenotransplantation model. SCID mice were injected with 518A2, Mel-JUSO, or 607B human melanoma cells. After they developed tumors, mice received daily CCI-779 or solvent over 14 days. From treatment day 4-8 mice were additionally injected with DTIC or saline. Treatment with CCI-779 plus DTIC was superior to single agent DTIC in two out of three cell lines (P<0.05). The tumor weight reduction was 44+/-17 and 61+/-6% compared with DTIC monotreatment in Mel-JUSO and 607B melanomas, respectively (P<0.05). In contrast, in 518A2 xenotransplants, CCI-779 plus DTIC treatment was as effective as DTIC monotreatment. CCI-779 monotherapy exerted no statistically significant antitumor effect. Collectively, these data indicate that CCI-779 has the potential to increase the chemotherapeutic efficacy, as the combination of CCI-779 plus DTIC proved to be more efficacious compared to DTIC monotherapy in two out of three melanoma cell lines in vivo.
Insights
The combination of cell cycle inhibitor-779 (CCI-779) and dacarbazine (DTIC) showed improved efficacy against metastatic melanoma compared to DTIC alone in preclinical models. CCI-779 monotherapy did not demonstrate significant antitumor effects.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Metastatic melanoma remains a significant challenge in cancer treatment.
- Dacarbazine (DTIC) is a standard chemotherapy for metastatic melanoma.
- Novel therapeutic strategies are needed to improve treatment outcomes.
Purpose of the Study:
- To evaluate the antineoplastic potential of combining cell cycle inhibitor-779 (CCI-779) with dacarbazine (DTIC).
- To compare the efficacy of the combination therapy against DTIC monotherapy in a preclinical melanoma model.
Main Methods:
- A severe combined immunodeficiency (SCID)-mouse xenotransplantation model was utilized.
- Human melanoma cell lines (518A2, Mel-JUSO, 607B) were xenografted into SCID mice.
- Mice received daily CCI-779 or solvent, with DTIC or saline administered during specific treatment days.
Main Results:
- The combination of CCI-779 plus DTIC demonstrated superior efficacy over DTIC monotherapy in two of three melanoma cell lines.
- Significant tumor weight reductions of 44% (Mel-JUSO) and 61% (607B) were observed with combination therapy.
- CCI-779 monotherapy showed no statistically significant antitumor effect.
Conclusions:
- The combination of CCI-779 and DTIC holds potential for enhancing chemotherapeutic efficacy in metastatic melanoma.
- CCI-779 may serve as a valuable adjunct to existing chemotherapy regimens.
- Further investigation into this combination therapy is warranted for clinical application.
